Braham Shroot, Ph.D. has been appointed chief scientific officer of Barrier Therapeutics. In this role, he will manage the company’s R&D activities, reporting to Geert Cauwenbergh, Ph.D., chief executive officer.

“Dr. Shroot’s extensive scientific background, as well as his established record in dermatological product development, makes him an ideal leader for Barrier’s research and development organization, where we have a broad pipeline of product candidates for the treatment of dermatological conditions, including onychomycosis, psoriasis, acne, skin allergies, and acute fungal infections,” said Dr. Cauwenbergh. “Braham is an internationally recognized leader in dermatology by the industry as well as by academia, and we welcome him to Barrier.”

Dr. Shroot joins the company with more than 35 years of experience in dermatology drug development. Most recently, he served as chief scientific officer, vice president of R&D for DFB Pharmaceuticals, a specialty pharmaceutical company with branded products that treat skin and soft tissue disorders. Prior to DFB, Dr. Shroot spent 13 years in various R&D positions with Galderma S.A., including serving as president, Galderma Research, Inc. in the U.S. and as vice general manager of Galderma’s R&D organization in France. Dr. Shroot began his career in pharmaceuticals at Pfizer, where he was part of the team that developed fluconazole and thioconazole.

Chuck Nomides, Barrier’s chief R&D officer, will continue to oversee development activities under Dr. Shroot.